ORIGINAL CONTRIBUTION. Clinically Undetected Motor Neuron Disease in Pathologically Proven Frontotemporal Lobar Degeneration With Motor Neuron Disease
|
|
- Derrick Anthony
- 6 years ago
- Views:
Transcription
1 ORIGINAL CONTRIBUTION Clinically Undetected Motor Neuron Disease in Pathologically Proven Frontotemporal Lobar Degeneration With Motor Neuron Disease Keith A. Josephs, MST, MD; Joseph E. Parisi, MD; David S. Knopman, MD; Bradley F. Boeve, MD; Ronald C. Petersen, MD, PhD; Dennis W. Dickson, MD Background: Frontotemporal lobar degeneration with motor neuron disease (FTLD-MND) is a pathological entity characterized by motor neuron degeneration and frontotemporal lobar degeneration. The ability to detect the clinical signs of dementia and motor neuron disease in pathologically confirmed FTLD-MND has not been assessed. Objectives: To determine if all cases of pathologically confirmed FTLD-MND have clinical evidence of frontotemporal dementia and motor neuron disease, and to determine the possible reasons for misdiagnosis. Method: Review of historical records and semiquantitative analysis of the motor and extramotor pathological findings of all cases of pathologically confirmed FTLD-MND. Results: From a total of 17 cases of pathologically confirmed FTLD-MND, all had clinical evidence of frontotemporal dementia, while only 10 (59%) had clinical evidence of motor neuron disease. Semiquantitative analysis of motor and extramotor pathological findings revealed a spectrum of pathological changes underlying FTLD-MND. Hippocampal sclerosis, predominantly of the subiculum, was a significantly more frequent occurrence in the cases without clinical evidence of motor neuron disease (P.01). In addition, neuronal loss, gliosis, and corticospinal tract degeneration were less severe in the other 3 cases without clinical evidence of motor neuron disease. Conclusions: Clinical diagnostic sensitivity for the elements of FTLD-MND is modest and may be affected by the fact that FTLD-MND represents a spectrum of pathological findings, rather than a single homogeneous entity. Detection of signs of clinical motor neuron disease is also difficult when motor neuron degeneration is mild and in patients with hippocampal sclerosis. Arch Neurol. 2006;63: Author Affiliations: Departments of Neurology (Drs Josephs, Knopman, Boeve, and Petersen) and Laboratory Medicine and Pathology (Dr Parisi), Mayo Clinic, Rochester, Minn; Department of Pathology and Neuroscience (Dr Dickson), Mayo Clinic, Jacksonville, Fla. FRONTOTEMPORAL DEMENTIA () is a clinical term applied to patients who present with progressive dementia with an insidious onset, prominent behavioral or language dysfunction, or both. Motor neuron disease (MND) is also a clinical term, but it is applied to patients with clinical evidence of corticospinal tract involvement, evidence of brainstem or spinal cord anterior horn cell involvement, or both. Recent studies have revealed that clinical features of and MND () can occur in the same patient and not infrequently. 1-3 For editorial comment see page 489 As with the clinical syndrome of - MND, pathologic studies have independently identified cases with frontotemporal lobar degeneration and features of typical motor neuron degeneration (FTLD- MND). 4 Therefore, FTLD-MND currently represents a distinct pathological entity. During the last decade, we and others have observed cases that at autopsy have had histologic evidence of mixed features of FTLD and MND. Furthermore, clinical studies have revealed an increased frequency of MND in cases of, 3 and an increased frequency of in cases of MND. 2 Unfortunately, studies correlating the clinical signs of - MND with the pathologic diagnosis of FTLD-MND are limited. 5 We therefore set out to assess the association of clinical features of and pathologically confirmed FTLD-MND. METHODS CASE ASCERTAINMENT The Mayo Clinic (Rochester, Minn) pathological database was searched to identify all cases that were autopsied with a pathological diagnosis of Pick disease, FTLD-MND, or demen- 506
2 tia lacking distinctive histopathologic features. We also reviewed our cases of FTLD, but none had pathologic evidence of motor neuron degeneration. 6 All identified cases were then reexamined pathologically with modern neuropathologic stains. Only cases with a final diagnosis of FTLD-MND were retained for this study. A retrospective review of the historical records of all cases with final pathological diagnosis of FTLD-MND was undertaken. Special attention was paid to any sign or symptom suggestive of bulbar dysfunction, upper or lower motor neuron disease (or both), and the treating physician s diagnoses at onset and throughout the disease course. PATHOLOGICAL ANALYSIS In all cases identified from the previously described electronic search, slides of frontal, temporal, and parietal neocortex, hippocampus, basal ganglia, thalamus, midbrain, pons, medulla, and cerebellum were reviewed. In all cases, sections were studied with hematoxylin-eosin (HE) and modified Bielschowsky staining, as well as other stains needed for routine evaluation, including immunohistochemistry for markers of glial pathology. Those stains include glial fibrillary acid protein for astrocytes and either CD68 or HLA-DR antigens for microglia. Neuronal pathology was studied with antibodies to neurofilament protein, ubiquitin, -synuclein, and phospho-tau. In all cases, the hypoglossal nucleus and/or cervical spinal anterior horn cells were reviewed for evidence of motor neuron degeneration with HE and ubiquitin. In many cases, stains for glial fibrillary acidic protein and macrophages were also available. Neuronal loss and gliosis were assessed semiquantitatively in the hypoglossal nucleus and the anterior horn cells of the spinal cord with a 4-point scale (0=none; 1 =focal neuronal loss and focal microgliosis; 2 =extensive neuronal loss with microgliosis and empty cell beds containing macrophages; 3 =almost complete loss of motor neurons with atrophy and astrocytic fibrillar gliosis). The presence of Bunina bodies was assessed on HE staining in motor neurons of the hypoglossal nucleus and spinal anterior horn cells. Lewy body like hyaline inclusions were assessed on HE staining and ubiquitin stains. Skeinlike and pleomorphic cytoplasmic inclusions were assessed on ubiquitin immunostains. The corticospinal tract was assessed for wallerian degeneration using HE (presence of atrophy with vacuolation and lipid-laden macrophages), myelin stains (pallor on Luxol fast blue), or macrophage stains (increased ameboid microglia) paying special attention to the pyramids in the medulla and the lateral funiculi in the spinal cord. The severity of corticospinal tract degeneration was assessed semiquantitatively on a 5-point scale (0=none, 1 =very mild vacuolation and sparse macrophages; 2 =vacuolation with many lipid-laden macrophages; 3 =many lipid-laden macrophages with myelin loss; 4 =myelinated fiber loss, tract atrophy and astrocytic gliosis). Extramotor inclusions were assessed semiquantitatively with ubiquitin immunostains with a 5-point grading scale (0=none; 0-1 =isolated; 1 =sparse; 2 =moderate; 3 =frequent number). Histopathologic analysis was conducted by neuropathologists with expertise in degenerative neuropathology (J.E.P. and D.W.D.). Semiquantitative analysis was conducted by a neuropathologist (D.W.D.). Frontotemporal lobar degeneration with motor neuron disease (Figure 1) was diagnosed if there was evidence of brainstem or spinal cord anterior horn cell degeneration or degeneration of the corticospinal tract, or both, in addition to histologic evidence of frontotemporal lobar degeneration. Histologic evidence of motor neuron degeneration included loss of large anterior horn cells in the spinal cord or hypoglossal motor neurons plus (1) shrunken residual motor neurons, (2) evidence of neuronophagia, (3) Bunina bodies, or (4) ubiquitinimmunoreactive intraneuronal inclusions, including Lewy body like hyaline inclusions, skeinlike inclusions, or pleomorphic cytoplasmic inclusions, which were grouped with skeinlike inclusions for the purpose of analysis. Evidence of frontotemporal lobar degeneration included the presence of superficial spongiosis, neuronal loss, and astrogliosis affecting predominantly layer II of the cortex, with or without the presence of ubiquitinimmunoreactive neuronal cytoplasmic inclusions. Neuronal intranuclear inclusions were not detected. STATISTICAL ANALYSIS Statistical analyses were performed with SigmaStat software (Systat Software Inc, Point Richmond, Calif). Univariate correlations for analysis of clinical and pathologic factors used Spearman rank order correlation analysis. A P value of less than.05 was considered significant. RESULTS We identified 18 cases that fulfilled pathological criteria for FTLD-MND, including presence of ubiquitinimmunoreactive neuronal inclusions in motor or extramotor neuronal populations or both in all cases. The ubiquitin-positive inclusions were negative for tau, -synuclein, and neurofilament. One case was removed from further analysis because of a clinical diagnosis of multiple sclerosis 20 years prior to death. The demographics of the other 17 cases are presented in Table 1. Of these, 13 (76%) were male. The mean age at onset and disease duration were 52 years and 2.3 years, respectively. CLINICAL FEATURES All patients had clinical features suggestive of frontotemporal dysfunction; however, only 10 cases carried a diagnosis of or a comparable diagnostic term (such as amyotrophic lateral sclerosis dementia or dementia with MND) prior to death. Of the other 7 cases, 4 were diagnosed as, 2 with a rapidly progressive dementing illness, and 1 as vs Alzheimer disease. All 10 cases with a clinical diagnosis of had evidence of motor neuron disease on clinical examination, while the other 7 did not. Two cases were initially diagnosed as only (data not shown); however, they later developed signs of MND and were subsequently diagnosed as. One of these 2 cases (case 13) developed signs of MND approximately 45 months after the onset of symptoms of. In addition to the features in keeping with a diagnosis of, 5 cases (cases 2, 3, 15, 16, and 17) also had symptoms of forgetfulness at initial examination. Memory impairment was not severe or more prominent than the other presenting features in any of these 5 cases. PATHOLOGIC FINDINGS Pathologic findings are presented in Table 2 and shown in Figure 1 and Figure 2. All cases met pathologic criteria for FTLD-MND. 4,7 The hypoglossal nucleus was 507
3 A B C D E F G H I J K L M N O P Q R Figure 1. Motor neuronal loss and gliosis (A-C), corticospinal tract degeneration (D-F), and motor neuron inclusions with routine histology (G-I) and with ubiquitin immunohistochemistry ( J-R). A, Anterior horn cell neuronal loss and gliosis. B, Anterior horn cell gliosis (glial fibrillary acidic protein). C, Hypoglossal nucleus microgliosis (HLA-DR antigens). D, Pyramidal degeneration and lipid-laden macrophages (arrows). E, Pyramidal myelin loss (Luxol fast blue stain). F, Pyramidal macrophages (HLA-DR antigens). G and I, Lewy body like inclusions anterior horn cells (arrows). H and I, Bunina bodies (arrowheads). J-M, Skeinlike inclusions. N and O, Lewy body like inclusions. P-R, Pleomorphic inclusions (for all figures, hematoxylin-eosin stain was used unless otherwise noted, original magnification 400). 508
4 Table 1. Demographics of 17 Cases of FTLD-MND* Case, No. /Sex Age at Onset, y Age at Death, y Disease Duration, y STMSS on Initial Examination Prominent Symptoms Early in Disease Course, (Less Prominent Symptoms) 1/F /38 Personality change, combative, agitative 2/F /38 Personality change, socially withdrawn, (forgetful) 3/F NA Behavioral dyscontrol, paranoia, pacing, and roaming, (forgetful) 4/M NA Inappropriate behaviors, apathetic, (unusual spontaneous laughter) 5/M /38 Personality change, apathetic, weight gain, inability to follow through 6/M /38 Socially withdrawn, emotional blunting, aphasia, easily distracted 7/M /38 Behavioral dyscontrol, hyperorality, visual hallucinations, (incontinence of urine) 8/M /38 Personality change, tangentional and circumstantial in language 9/M /38 Language difficulties, slowed speech, swallowing difficulties 10/M /38 Agitation, personality change, less interactive, rapid loss of verbal output 11/M NT Emotional blunting, irritability, decline in communication 12/F /38 Paranoia, difficulty with planning, organizing, speaking, (swallowing) 13/M /38 Personality change, sexual indiscretions, delusions involving bugs, lack of spontaneity 14/M /38 Personality change, apathetic, difficulty processing information 15/M /38 Irritability, anomia, (forgetful), spells of confusion, 1 hallucination seeing elves 16/M NA Language difficulties, slowed speech, (forgetful) 17/M NA Difficulty with speech, (forgetful), depression, difficulty performing job duties Abnormal Cranial Nerve and Motor Neuron Findings During Illness Babinski sign mixed spastic-flaccid dysarthria, Babinski sign Babinski sign, infrequent fasciculations Spastic dysarthria, fasciculations, tongue weakness Mixed spastic-flaccid dysarthria muscle atrophy Mixed spastic-flaccid dysarthria, prominent fasciculations Babinski sign, muscle wasting mild weakness, muscle atrophy Spasticity, spastic dysarthria, Babinski sign, prominent fasciculations Final Clinical Diagnosis RPD vs AD RP- Dementia/MND Dementia/ALS Dementia/ALS Dementia/MND Abbreviations: AD, Alzheimer disease; ALS, amyotrophic lateral sclerosis;, frontotemporal dementia; FTLD-MND, frontotemporal lobar degeneration with motor neuron disease; MND, motor neuron disease; NA, not able to be tested (either too severely affected or anarthric); NT, not tested (evaluated in 1986 before publication of the STMSS); RPD, rapidly progressive dementia; RP-, rapidly progressive frontotemporal dementia; STMSS, Short Test of Mental Status score. *Group 1 (cases 1-7); group 2 (cases 8-17). These cases were clinically diagnosed between 1987 and 1991 and explain the older terminology. available for review in 16 cases. In 14 cases, the cervical spinal cord, but more often multiple levels of spinal cord, were available for study. Bunina bodies were found in 14 cases and skeinlike inclusions, pleomorphic inclusions, or Lewy body like hyaline inclusions in motor neurons were found in 11 cases. Extramotor ubiquitin-positive neuronal inclusions were present in all cases, in the dentate fascia, neocortex, or both regions. Four cases had evidence of hippocampal sclerosis predominantly affecting the subiculum. Additional pathologic findings were present in a number of cases including 2 cases with skeletal muscle from the general autopsy; both had evidence of group atrophy with small acutely angulated fibers consistent with neurogeneic atrophy. SEMIQUANTITATIVE RESULTS Semiquantitative results are presented in Table 2. Neuronal loss and gliosis of the hypoglossal nucleus and spinal anterior horn cells were variable and ranged from 509
5 Table 2. Semiquantitative Data of Motor and Extramotor Neuron Pathologic Findings in FTLD-MND* Case, No. Neuronal Loss and Gliosis Cranial Nerve XII Anterior Horn Cell Motor Inclusions (Ubiquitin) Cranial Nerve XII Anterior Horn Cell CST Degeneration Dentate Fascia Extramotor Inclusions (Ubiquitin) Cortical Inclusions Cortical Neurites Hippocampal Sclerosis Additional Pathological Findings No No SUB Mild CAA and senile changes 2 0 NA No NA SUB None 3 2 (BB) 1 (BB) No No SUB Alzheimer disease 4 1 (BB) NA Yes NA CA1, SUB None 5 1 (BB; LBHI) 1 (BB; LBHI) Yes No No None 6 1 (BB) 2 (BB) No Yes No Muscle neurogenic atrophy; none 7 1 (BB) NA No NA No None 8 2 (BB; LBHI) 2 (BB) Yes Yes No None 9 1 (BB; LBHI) 1 (BB) Yes Yes No Mild CAA 10 2 (BB) 2 (BB; LBHI) NA No No None 11 3 (BB; LBHI) 2 (BB; LBHI) Yes Yes No None 12 2 (BB) 2 (BB; LBHI) No Yes No None 13 2 (BB) 1 (BB; LBHI) Yes No No Muscle neurogenic atrophy; none 14 1 (BB; LBHI) 3 (BB) No Yes No None 15 1 (LBHI) 2 (LBHI) Yes Yes No Acute hem infarct; incidental Lewy bodies 16 1 (BB) 1 (BB) No No No None 17 NA 1 (BB) NA No No None Abbreviations: BB, Bunina bodies; CA1, cornu ammonis 1; CAA, cerebral amyloid angiopathy; CST, corticospinal tract; FTLD-MND, frontotemporal lobar degeneration with motor neuron disease; LBHI, Lewy body like hyaline inclusions; NA, not able to evaluate; SUB, subiculum. *Group 1 (cases 1-7); group 2 (cases 8-17). For neuronal loss and gliosis, 0 = none; 1 = focal neuronal loss and focal microgliosis; 2 = extensive neuronal loss with microgliosis and empty cell beds containing macrophages; 3 = almost complete loss of motor neurons with atrophy and astrocytic fibrillar gliosis. For severity of corticospinal tract degeneration, 0 = none; 1 = very mild vacuolation and sparse macrophages; 2 = vacuolation with many lipid-laden macrophages; 3 = many lipid-laden macrophages with myelin loss; 4 = myelinated fiber loss, tract atrophy, and astrocytic gliosis. For extramotor inclusions, 0 = none; 0-1 = isolated; 1 = sparse; 2 = moderate; 3 = frequent number. Difficult to exclude Alzheimer disease neurites and inclusions. A B C D E F Figure 2. A range of ubiquitin-positive inclusions in the dentate fascia including granular inclusions that are polarized or circumferential (A-C), as well as crescent-shaped inclusions (arrows), and round Pick body like inclusions (arrowheads) (D-F). It should be emphasized that Pick body like inclusions are the minority in frontotemporal lobar degeneration with motor neuron disease and granular-type inclusions are the most common (for all figures, hematoxylin-eosin stain was used unless otherwise noted, original magnification 400). 510
6 absent to severe, and the severity of motor neuron pathologic features tended to correlate with clinical evidence of motor neuron disease (r=0.63, P.05 for hypoglossal nucleus; r=0.57, P=.10 for anterior horn cells). Similarly, corticospinal tract degeneration ranged from absent to severe. Severity of corticospinal tract degeneration did not correlate with clinical signs of motor neuron disease or with severity of neuronal loss and gliosis in the hypoglossal nucleus and spinal anterior horn cells. There was a weak correlation between severity of corticospinal tract degeneration and cases with cortical ubiquitinpositive inclusions (r=0.50, P.05). Extramotor ubiquitin-positive inclusions were absent to sparse in all cortical regions (except case 3 for which it was difficult to exclude Alzheimer disease neurites and inclusions), and absent to moderate in the dentate fascia of the hippocampus in almost all cases. In only 3 cases with hippocampal sclerosis were there frequent inclusions in the dentate fascia. CLINICOPATHOLOGIC CORRELATION We divided the cases into the following 2 groups: group 1 consisted of those cases that were not clinically diagnosed as (cases 1-7) and group 2 consisted of those that were clinically diagnosed as (cases 8-17). Four of the 7 cases from group 1, but none of the 10 cases from group 2, were found to have hippocampal sclerosis (3 of which also had frequent inclusions in the dentate fascia). In addition, the other 3 cases from group 1 (those without hippocampal sclerosis) were found to have minimal neuronal loss in hypoglossal nucleus and anterior horn cells as well as absent to minimal corticospinal tract degeneration. In contrast, the cases from group 2 had moderate to severe neuronal loss in the hypoglossal nucleus and anterior horn cells, moderate to severe corticospinal tract degeneration, or a mixture of both. Only case 16 from group 2 had minimal hypoglossal and anterior horn cell pathologic features. Spearman rank order correlation confirmed our observations and demonstrated that cases from group 1 were significantly more likely to have hippocampal sclerosis (r=0.70, P.01). Patients from group 1 also tended to be female (r=0.44, P=.08) and hippocampal sclerosis was significantly correlated with female sex (r=0.67, P.01). COMMENT This study demonstrates many important features regarding the co-occurrence of frontotemporal lobar degeneration and motor neuron disease. As expected, all 17 cases had neuronal loss and gliosis affecting the frontal and temporal cortices in keeping with a diagnosis of frontotemporal lobar degeneration. In addition, all cases had pathologic evidence of one form of motor neuron degeneration. Therefore, they were appropriately categorized as FTLD-MND. Furthermore, all 17 cases met pathologic criteria for FTLD-MND. 4,7 The pathologic features of FTLD-MND were variable. Most cases had a mixture of lower motor neuron degeneration and corticospinal tract degeneration, similar to amyotrophic lateral sclerosis, and the majority had Bunina bodies, which are a histologic hallmark of amyotrophic lateral sclerosis. The severity of motor neuron degeneration was variable and ranged from absent to severe. We found that some cases had a predominance of corticospinal tract degeneration (cases 1, 2, 4, 8, 9, 10, and 17), while others had no corticospinal tract degeneration (cases 3, 7, 14, and 15). Extramotor ubiquitinpositive pathologic findings were minimal overall and mostly granular in all cases. Despite these differences, at the present time there is no way to distinguish between cases on the basis of extramotor ubiquitin-positive pathologic features or on the basis of predominant involvement of upper or lower motor neurons. A larger sample size would be needed to address possible clinically useful subtypes. Four of the 7 cases without clinical evidence of motor neuron disease had hippocampal sclerosis, predominantly of the subicular region. Hippocampal sclerosis is a common feature of frontotemporal lobar degeneration with ubiquitin-only immunoreactive changes. 8,9 In addition, 3 of these 4 cases had frequent ubiquitinpositive inclusions in the dentate fascia of the hippocampus, which is another common feature of frontotemporal lobar degeneration with ubiquitin-only immunoreactive changes. We therefore argue that FTLD- MND should be thought of as a spectrum of diseases and include FTLD-MND with hippocampal sclerosis and FTLD-MND without hippocampal sclerosis. Frontotemporal lobar degeneration with motor neuron disease with hippocampal sclerosis seemed strikingly similar to other frontotemporal lobar degenerations with some evidence of MND, while FTLD-MND without hippocampal sclerosis seemed strikingly similar to amyotrophic lateral sclerosis with some evidence of FTLD. Fibers from the subiculum serve as the major output center for the hippocampus. Therefore, the cases with hippocampal sclerosis predominantly affecting the subiculum were likely to be more amnestic and impaired, which may explain why features of motor neuron disease were not clinically detected in these 4 cases with moderate motor neuron degeneration. Two of these 4 cases were so impaired that a mental status examination was not possible, the third was severely demented with a score of 13 out of 38 on the Short Test of Mental Status, 10 and the fourth was moderately to severely demented with a score of 21 out of 38. Three of the 7 cases with clinically undetected motor neuron disease, however, did not have hippocampal sclerosis. Semiquantitative analysis in these cases revealed very mild motor neuron pathological features. Therefore, another reason for inability to clinically detect motor neuron disease without the aid of detailed and specialized electrophysiologic studies or muscle biopsy may be very mild subclincal motor neuron degeneration. Routine electromyography had been completed in 2 of the 7 cases without clinical detection of motor neuron disease; in 1 case (case 7), electromyographic recordings had been taken 6 months prior to death and revealed normal findings. All 17 cases had clinical evidence of frontotemporal impairment and met research criteria for a diagnosis of 511
7 . 11 Five of the cases also had symptoms of mild forgetfulness in addition to the more prominent behavioral features. This is not surprising because memory loss is not an uncommon symptom or sign in. 12 We also show in this study that when and MND co-occur, signs of MND may not always be present early. In 2 cases, only features of dementia were noted early in the disease course and both initially carried a diagnosis of. Both cases later developed signs of MND. Surprisingly, in 1 of the 2 cases (case 16), there was no evidence of MND until almost 4 years into the disease course. Prior studies had suggested that MND typically postdates the onset of dementia by 6 to 26 months. 13,14 This study extends this interval to approximately 45 months. We did not find any cases of spinal cord anterior horn cell degeneration without hypoglossal nucleus involvement and we do not know if such cases exist. Therefore, spinal cord harvesting and analysis are of the utmost importance for future clinicopathologic studies in cases with combined dementia and motor neuron disease. Accepted for Publication: August 31, Correspondence: Keith A. Josephs, MST, MD, Department of Neurology, Mayo Clinic, 200 First St SW, Rochester, MN (josephs.keith@mayo.edu). Author Contributions: Study concept and design: Josephs, Parisi, Knopman, Boeve, and Petersen. Acquisition of data: Josephs, Parisi, Knopman, Boeve, and Dickson. Analysis and interpretation of data: Josephs, Parisi, Boeve, Petersen, and Dickson. Drafting of the manuscript: Josephs, Parisi, and Petersen. Critical revision of the manuscript for important intellectual content: Josephs, Parisi, Knopman, Boeve, and Dickson. Obtained funding: Petersen. Administrative, technical, and material support: Josephs, Parisi, Boeve, and Dickson. Study supervision: Parisi and Knopman. Funding/Support: This study was supported by grants P50-AG16574 and U01-AG06786 from the National Institute on Aging, Bethesda, Md, and by the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer s Disease Research Programs of the Mayo Foundation. Acknowledgment: Phospho-tau was a gift from Peter Davies, PhD, Albert Einstein College of Medicine, Bronx, NY. REFERENCES 1. Caselli RJ, Windebank AJ, Petersen RC, et al. Rapidly progressive aphasic dementia and motor neuron disease. Ann Neurol. 1993;33: Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology. 2003; 60: Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology. 2002;59: Lowe J, Rossor MN. Frontotemporal lobar degeneration. In: Dickson DW, ed. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Basel, Switzerland: ISN Neuropath Press; 2003: Hodges JR, Davies RR, Xuereb JH, et al. Clinicopathological correlates in frontotemporal dementia. Ann Neurol. 2004;56: Josephs KA, Petersen RC, Knopman DS, et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology. 2006; 66: McKhann GM, Albert MS, Grossman M, et al. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick s Disease. Arch Neurol. 2001;58: Josephs KA, Jones AG, Dickson DW. Hippocampal sclerosis and ubiquitinpositive inclusions in dementia lacking distinctive histopathology. Dement Geriatr Cogn Disord. 2004;17: Hatanpaa KJ, Blass DM, Pletnikova O, et al. Most cases of dementia with hippocampal sclerosis may represent frontotemporal dementia. Neurology. 2004; 63: Kokmen E, Naessens JM, Offord KP. A short test of mental status: description and preliminary results. Mayo Clin Proc. 1987;62: Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51: Graham A, Davies R, Xuereb J, et al. Pathologically proven frontotemporal dementia presenting with severe amnesia. Brain. 2005;128: Mitsuyama Y. Dementia with motor neuron disease. Neuropathology. 2000;20(Suppl):S79-S Mitsuyama Y. Presenile dementia with motor neuron disease in Japan: clinicopathological review of 26 cases. J Neurol Neurosurg Psychiatry. 1984;47: Announcement Visit As an individual subscriber to Archives of Neurology, you have full-text online access to the journal from 1998 forward. In addition, you can find abstracts to the journal as far back as
ORIGINAL CONTRIBUTION
ORIGINAL CONTRIBUTION Frontotemporal Lobar Degeneration Without Lobar Atrophy Keith A. Josephs, MST, MD; Jennifer L. Whitwell, PhD; Clifford R. Jack, MD; Joseph E. Parisi, MD; Dennis W. Dickson, MD Background:
More informationAmyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative
ORIGINAL RESEARCH E. Matsusue S. Sugihara S. Fujii T. Kinoshita T. Nakano E. Ohama T. Ogawa Cerebral Cortical and White Matter Lesions in Amyotrophic Lateral Sclerosis with Dementia: Correlation with MR
More informationI do not have any disclosures
Alzheimer s Disease: Update on Research, Treatment & Care Clinicopathological Classifications of FTD and Related Disorders Keith A. Josephs, MST, MD, MS Associate Professor & Consultant of Neurology Mayo
More informationRole of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases
Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases Keith A. Josephs, MD, MST, MSc Professor of Neurology 13th Annual Mild Cognitive Impairment (MCI) Symposium: Alzheimer and Non-Alzheimer
More informationNeuropathology of Neurodegenerative Disorders Prof. Jillian Kril
Neurodegenerative disorders to be discussed Alzheimer s disease Lewy body diseases Frontotemporal dementia and other tauopathies Huntington s disease Motor Neuron Disease 2 Neuropathology of neurodegeneration
More informationClinicopathologic and genetic aspects of hippocampal sclerosis. Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA
Clinicopathologic and genetic aspects of hippocampal sclerosis Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA The hippocampus in health & disease A major structure of the medial temporal
More informationORIGINAL CONTRIBUTION. Survival Profiles of Patients With Frontotemporal Dementia and Motor Neuron Disease
ORIGINAL CONTRIBUTION Survival Profiles of Patients With Frontotemporal Dementia and Motor Neuron Disease William T. Hu, MD, PhD; Harro Seelaar; Keith A. Josephs, MST, MD; David S. Knopman, MD; Bradley
More informationNACC Vascular Consortium. NACC Vascular Consortium. NACC Vascular Consortium
NACC Vascular Consortium NACC Vascular Consortium Participating centers: Oregon Health and Science University ADC Rush University ADC Mount Sinai School of Medicine ADC Boston University ADC In consultation
More informationThe Spectrum of Age-Associated Astroglial Tauopathies. Dennis W. Dickson MD Department of Neuroscience Mayo Clinic, Jacksonville, FL
The Spectrum of Age-Associated Astroglial Tauopathies Dennis W. Dickson MD Mayo Clinic, Jacksonville, FL Thorn-shaped astrocytes TSA were first reported by Ikeda (1995), as tau-positive astrocytes in various
More information! slow, progressive, permanent loss of neurologic function.
UBC ! slow, progressive, permanent loss of neurologic function.! cause unknown.! sporadic, familial or inherited.! degeneration of specific brain region! clinical syndrome.! pathology: abnormal accumulation
More informationFTD basics! Etienne de Villers-Sidani, MD!
FTD basics! Etienne de Villers-Sidani, MD! Frontotemporal lobar degeneration (FTLD) comprises 3 clinical syndromes! Frontotemporal dementia (behavioral variant FTD)! Semantic dementia (temporal variant
More informationDementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada
Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends
More informationLower Motor Neuron Involvement in TAR DNA-Binding Protein of 43 kda Related Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Research Original Investigation Lower Motor Neuron Involvement in TAR DNA-Binding Protein of 43 kda Related Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis Yuichi Riku, MD; Hirohisa
More informationPerspectives on Frontotemporal Dementia and Primary Progressive Aphasia
Perspectives on Frontotemporal Dementia and Primary Progressive Aphasia Bradley F. Boeve, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Alzheimer s Disease
More informationUpper and Lower Motoneurons for the Head Objectives
Upper and Lower Motoneurons for the Head Objectives Know the locations of cranial nerve motor nuclei Describe the effects of motor cranial nerve lesions Describe how the corticobulbar tract innervates
More informationSUPPLEMENTARY INFORMATION
doi:10.1038/nature10353 Supplementary Figure 1. Mutations of UBQLN2 in patients with ALS and ALS/dementia. (a) A mutation, c.1489c>t (p.p497s), was identified in F#9975. The pedigree is shown on the left
More informationBrain dissection protocol for amyotrophic lateral sclerosis/motor neurone disease
Brain dissection protocol for amyotrophic lateral sclerosis/motor neurone disease Prepared by Approved by Approved by Revised by Name Signature Date Sampling and biomarker OPtimization and Harmonization
More informationMild Cognitive Impairment (MCI)
October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine
More informationALS, Cognitive Impairment (CI) and Frontotemporal Lobar Dementia (FTLD): A Professional s Guide
ALS, Cognitive Impairment (CI) and Frontotemporal Lobar Dementia (FTLD): A Professional s Guide Overview A link between ALS and cognitive dysfunction was first noted in the late 1800 s, but only in the
More informationDementia and Healthy Ageing : is the pathology any different?
Dementia and Healthy Ageing : is the pathology any different? Professor David Mann, Professor of Neuropathology, University of Manchester, Hope Hospital, Salford DEMENTIA Loss of connectivity within association
More informationDementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology
Dementia Stephen S. Flitman, MD Medical Director 21st Century Neurology www.neurozone.org Dementia is a syndrome Progressive memory loss, plus Progressive loss of one or more cognitive functions: Language
More informationFRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS
FRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS Norman L. Foster, M.D. Director, Center for Alzheimer s Care, Imaging and Research Chief, Division of Cognitive Neurology, Department of Neurology
More informationThe frontotemporal dementia spectrum what the general physician needs to know Dr Jonathan Rohrer
The frontotemporal dementia spectrum what the general physician needs to know Dr Jonathan Rohrer MRC Clinician Scientist Honorary Consultant Neurologist Dementia Research Centre, UCL Institute of Neurology
More informationClinical phenotypes in autopsy-confirmed Pick disease
Clinical phenotypes in autopsy-confirmed Pick disease O. Piguet, PhD G.M. Halliday, PhD W.G.J. Reid, PhD B. Casey, PhD R. Carman, MPhil Y. Huang, PhD J.H. Xuereb, MD J.R. Hodges, FRCP J.J. Kril, PhD Address
More informationORIGINAL CONTRIBUTION. Rapidly Progressive Neurodegenerative Dementias
ORIGINAL CONTRIBUTION Rapidly Progressive Neurodegenerative Dementias Keith A. Josephs, MD; J. Eric Ahlskog, PhD, MD; Joseph E. Parisi, MD; Bradley F. Boeve, MD; Brian A. Crum, MD; Caterina Giannini, MD;
More information2016 Programs & Information
Mayo Alzheimer s Disease Research Clinic Education Center 2016 Programs & Information BROCHURE TITLE FLUSH RIGHT for Persons & Families impacted by Mild Cognitive Impairment Alzheimer s Disease Dementia
More informationClinicopathological and imaging correlates of progressive aphasia and apraxia of speech
doi:10.1093/brain/awl078 Brain (2006), 129, 1385 1398 Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech Keith A. Josephs, 1,2 Joseph R. Duffy, 3 Edyth A. Strand, 3
More informationDementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota
Dementia Update Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Nothing to disclose Dementia Progressive deterioration in mental function
More informationDISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT
Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease
More informationObjectives. Objectives continued: 3/24/2012. Copyright Do not distribute or replicate without permission 1
Frontotemporal Degeneration and Primary Progressive Aphasia Caregiver and Professional Education Conference Diana R. Kerwin, MD Assistant Professor of Medicine-Geriatrics Cognitive Neurology and Alzheimer
More informationFinal Scientific Progress Report
CUREPSP Final Scientific Progress Report Tau in Peripheral Tissues of PSP and CBD. Brittany Dugger, PhD; University of California San Francisco Specific Aim: Using immunohistochemical methods on autopsy
More informationBrainstem. Steven McLoon Department of Neuroscience University of Minnesota
Brainstem Steven McLoon Department of Neuroscience University of Minnesota 1 Course News Change in Lab Sequence Week of Oct 2 Lab 5 Week of Oct 9 Lab 4 2 Goal Today Know the regions of the brainstem. Know
More informationALS and Frontotemporal Dementia. Catherine Lomen-Hoerth, MD, PhD Professor of Neurology University of California, San Francisco
ALS and Frontotemporal Dementia Catherine Lomen-Hoerth, MD, PhD Professor of Neurology University of California, San Francisco Clinical Features Upper motor neuron findings Slow speech Brisk gag and jaw
More informationORIGINAL CONTRIBUTION. Apolipoprotein E 4 Is a Determinant for Alzheimer-Type Pathologic Features in Tauopathies, Synucleinopathies,
ORIGINAL CONTRIBUTION Apolipoprotein E 4 Is a Determinant for Alzheimer-Type Pathologic Features in Tauopathies, Synucleinopathies, and Frontotemporal Degeneration Keith A. Josephs, MST, MD; Yoshio Tsuboi,
More informationY. Zhang N. Schuff S. Woolley. L. Boreta
DTI in Amyotrophic Lateral Sclerosis. Jonathan Katz, MD Director, Neuromuscular Program Forbes Norris ALS-MDA Center California Pacific Medical Center Group Y. Zhang N. Schuff S. Woolley G. Chiang L. Boreta
More informationPathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)
Pathogenesis of Degenerative Diseases and Dementias D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Dementias Defined: as the development of memory impairment and other cognitive deficits
More informationNeurodegenerative diseases that degrade regions of the brain will eventually become
Maren Johnson CD 730 Research Paper What is the underlying neurological explanation for overeating in Frontotemporal Dementia? Does the change in overeating affect swallowing? Neurodegenerative diseases
More informationDEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD
DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD OBJECTIVES Terminology/Dementia Basics Most Common Types Defining features Neuro-anatomical/pathological underpinnings Neuro-cognitive
More informationThe ABCs of Dementia Diagnosis
The ABCs of Dementia Diagnosis Dr. Robin Heinrichs, Ph.D., ABPP Board Certified Clinical Neuropsychologist Associate Professor, Psychiatry & Behavioral Sciences Director of Neuropsychology Training What
More informationFunctional Distinctions
Functional Distinctions FUNCTION COMPONENT DEFICITS Start Basal Ganglia Spontaneous Movements Move UMN/LMN Cerebral Cortex Brainstem, Spinal cord Roots/peripheral nerves Plan Cerebellum Ataxia Adjust Cerebellum
More informationContents 1 Normal Histology and Commonly Used Stains 2 Basic Pathologic Reactions
Contents 1 Normal Histology and Commonly Used Stains.... 1 1.1 Cells of the Nervous System... 1 1.1.1 Neurons... 1 1.1.2 Astrocytes.... 2 1.1.3 Oligodendrocytes... 5 1.1.4 Schwann Cells... 5 1.1.5 Ependyma....
More informationNEUROPATHOLOGY BRAIN CUTTING MANUAL LAST UPDATED ON 6/22/2015
NEUROPATHOLOGY BRAIN CUTTING MANUAL LAST UPDATED ON 6/22/2015 Neuropathology Faculty involved in Brain Cutting: Dr. Sandra Camelo-Piragua Dr. Andrew Lieberman (Chief of the Division) Dr. Kathryn A. McFadden
More informationP20.2. Characteristics of different types of dementia and challenges for the clinician
P20.2. Characteristics of different types of dementia and challenges for the clinician, professor Danish Dementia Research Center Rigshospitalet, University of Copenhagen (Denmark) This project has received
More informationCN V! touch! pain! Touch! P/T!
CN V! touch! pain! Touch! P/T! Visual Pathways! L! R! B! A! C! D! LT! E! F! RT! G! hypothalamospinal! and! ALS! Vestibular Pathways! 1. Posture/Balance!!falling! 2. Head Position! 3. Eye-Head Movements
More informationForm D1: Clinician Diagnosis
Initial Visit Packet Form D: Clinician Diagnosis NACC Uniform Data Set (UDS) ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by the clinician.
More informationSupplementary Materials
Supplementary Materials Fig. S1. Weights of full-dose treatment groups comparing 1 st, 2 nd, and 3 rd generation gene replacement therapy. Mice were treated at p1 with 4x10 11 GC of the three different
More informationDo not copy or distribute without permission. S. Weintraub, CNADC, NUFSM, 2009
Sandra Weintraub, Ph.D. Clinical Core Director, Cognitive Neurology and Alzheimer s Disease Center Northwestern University Feinberg School of Medicine Chicago, Illinois Dementia: a condition caused by
More informationNACC Neuropathology (NP) Diagnosis Coding Guidebook
Department of Epidemiology, School of Public Health and Community Medicine, University of Washington 4311 11 th Avenue NE #300 Seattle, WA 98105 phone: (206) 543-8637; fax: (206) 616-5927 e-mail: naccmail@u.washington.edu
More informationVascular Cognitive Impairment-- NEUROPATHOLOGIC ISSUES. VCI vs. IVD/DEMENTIA with VASCULAR DISEASE (IVD) advanced pathology
Vascular Cognitive Impairment-- NEUROPATHOLOGIC ISSUES VCI vs. IVD/DEMENTIA with VASCULAR DISEASE (IVD) advanced pathology HANDLING the BRAIN at AUTOPSY: What to FIX vs. what to FREEZE? --no need to be
More information7/3/2013 ABNORMAL PSYCHOLOGY SEVENTH EDITION CHAPTER FOURTEEN CHAPTER OUTLINE. Dementia, Delirium, and Amnestic Disorders. Oltmanns and Emery
ABNORMAL PSYCHOLOGY SEVENTH EDITION Oltmanns and Emery PowerPoint Presentations Prepared by: Ashlea R. Smith, Ph.D. This multimedia and its contents are protected under copyright law. The following are
More informationTitle: Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease (NIFID)
Neurology/2004/048785 Title: Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease (NIFID) Correspondence to: Nigel J. Cairns PhD MRCPath Center for Neurodegenerative
More informationIntroduction and aims of the study
Introduction and aims of the study 1 Chapter 1 Motor neuron diseases include the most incapacitating and life-threatening illnesses but also rather benign disorders with only mild symptoms and slow progression.
More informationCommon Forms of Dementia Handout Package
Common Forms of Dementia Handout Package Common Forms of Dementia 1 Learning Objectives As a result of working through this module, you should be better able to: 1. Describe clinical features of 4 major
More informationAutopsy Committee Sample Autopsy Case. Alzheimer Disease. Authors Ashley Thorburn, MD. Joseph E. Parisi, MD Autopsy Committee
Autopsy Committee Sample Autopsy Case Alzheimer Disease Authors Ashley Thorburn, MD Joseph E. Parisi, MD Autopsy Committee Clinical Summary: A 75-year-old man presented to his primary care physician with
More informationEvidence of Multisystem Disorder in Whole-Brain Map of Pathological TDP-43 in Amyotrophic Lateral Sclerosis
ORIGINAL CONTRIBUTION Evidence of Multisystem Disorder in Whole-Brain Map of Pathological TDP-43 in Amyotrophic Lateral Sclerosis Felix Geser, MD; Nicholas J. Brandmeir, MS; Linda K. Kwong, PhD; Maria
More informationTDP-43 in the hypoglossal nucleus identifies amyotrophic lateral sclerosis in
TDP-43 in the hypoglossal nucleus identifies amyotrophic lateral sclerosis in behavioral variant frontotemporal dementia Glenda M Halliday a,b, Matthew C Kiernan c, Jillian J Kril d, Remika Mito d, Masami
More informationObjectives. Overview. Why FTD and AD? FTD May Mimic AD. Introduction and Process Norman L. Foster, MD. Introduction and Process 7BS.
Introduction and Process Norman L. Foster, MD 7BS.006 IMPROVING ACCURACY OF DEMENTIA DIAGNOSIS: CASE STUDIES WITH NEUROPATHOLOGY Norman L. Foster, MD University of Utah Salt Lake City, UT Edward Zamrini,
More informationFTD/PPA Caregiver Education Conference March 11, 2011
FTD/PPA Caregiver Education Conference March 11, 2011 Question and Answer Session Answered by Joseph Cooper, MD, Darby Morhardt, MSW, LCSW, Mary O Hara, AM, LCSW, Jaimie Robinson, MSW, LCSW, Emily Rogalski,
More information10/3/2016. T1 Anatomical structures are clearly identified, white matter (which has a high fat content) appears bright.
H2O -2 atoms of Hydrogen, 1 of Oxygen Hydrogen just has one single proton and orbited by one single electron Proton has a magnetic moment similar to the earths magnetic pole Also similar to earth in that
More informationMovement Disorders. Psychology 372 Physiological Psychology. Background. Myasthenia Gravis. Many Types
Background Movement Disorders Psychology 372 Physiological Psychology Steven E. Meier, Ph.D. Listen to the audio lecture while viewing these slides Early Studies Found some patients with progressive weakness
More informationMOTOR NEURONE DISEASE
MOTOR NEURONE DISEASE Dr Arun Aggarwal Department of Rehabilitation Medicine, RPAH Department of Neurology, Concord Hospital. Motor Neurone Disease Umbrella term in UK and Australia (ALS in USA) Neurodegenerative
More informationSimulated brain biopsy for diagnosing neurodegeneration using autopsy-confirmed cases
Acta Neuropathol (2011) 122:737 745 DOI 10.1007/s00401-011-0880-5 ORIGINAL PAPER Simulated brain biopsy for diagnosing neurodegeneration using autopsy-confirmed cases Sriram Venneti John L. Robinson Subhojit
More informationFor carers and relatives of people with frontotemporal dementia and semantic dementia. Newsletter
For carers and relatives of people with frontotemporal dementia and semantic dementia Newsletter AUGUST 2008 1 Welcome Welcome to the August edition of our CFU Support Group Newsletter. Thanks to all of
More informationChronic Traumatic Encephalopathy Provider and Parent Essentials
Chronic Traumatic Encephalopathy Provider and Parent Essentials Concussion Global Cast July 30, 2014 John Lockhart, MD Seattle Children s Hospital Chronic Traumatic Encephaly (CTE) Working Definition Chronic
More informationCurrent Concepts in the Classification and Diagnosis of Frontotemporal Lobar Degenerations
Current Concepts in the Classification and Diagnosis of Frontotemporal Lobar Degenerations Frontotemporal lobar degenerations are clinically, genetically, and molecularly heterogeneous diseases characterized
More informationForm A3: Subject Family History
Initial Visit Packet NACC Uniform Data Set (UDS) Form A: Subject Family History ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by a clinician
More informationCaring Sheet #11: Alzheimer s Disease:
CARING SHEETS: Caring Sheet #11: Alzheimer s Disease: A Summary of Information and Intervention Suggestions with an Emphasis on Cognition By Shelly E. Weaverdyck, PhD Introduction This caring sheet focuses
More informationThe Nervous System. Divisions of the Nervous System. Branches of the Autonomic Nervous System. Central versus Peripheral
The Nervous System Divisions of the Nervous System Central versus Peripheral Central Brain and spinal cord Peripheral Everything else Somatic versus Autonomic Somatic Nerves serving conscious sensations
More informationDelirium & Dementia. Nicholas J. Silvestri, MD
Delirium & Dementia Nicholas J. Silvestri, MD Outline Delirium vs. Dementia Neural pathways relating to consciousness Encephalopathy Stupor Coma Dementia Delirium vs. Dementia Delirium Abrupt onset Lasts
More informationCheyenne 11/28 Neurological Disorders II. Transmissible Spongiform Encephalopathy
Cheyenne 11/28 Neurological Disorders II Transmissible Spongiform Encephalopathy -E.g Bovine4 Spongiform Encephalopathy (BSE= mad cow disease), Creutzfeldt-Jakob disease, scrapie (animal only) -Sporadic:
More informationSECTION 1: as each other, or as me. THE BRAIN AND DEMENTIA. C. Boden *
I read all the available books by other [people with] Alzheimer s disease but they never had quite the same problems as each other, or as me. I t s not like other diseases, where there is a standard set
More informationORIGINAL CONTRIBUTION. Neuropathologic Outcome of Mild Cognitive Impairment Following Progression to Clinical Dementia
ORIGINAL CONTRIBUTION Neuropathologic Outcome of Mild Cognitive Impairment Following Progression to Clinical Dementia Gregory A. Jicha, MD, PhD; Joseph E. Parisi, MD; Dennis W. Dickson, MD; Kris Johnson,
More informationInfiltrative Brain Mass Due To Progressive Alzheimer's Disease
Article ID: WMC00505 2046-1690 Infiltrative Brain Mass Due To Progressive Alzheimer's Disease Corresponding Author: Dr. Mark Lyons, Associate Professor, Mayo Clinic Arizona, 85054 - United States of America
More informationNon Alzheimer Dementias
Non Alzheimer Dementias Randolph B Schiffer Department of Neuropsychiatry and Behavioral Science Texas Tech University Health Sciences Center 9/11/2007 Statement of Financial Disclosure Randolph B Schiffer,,
More informationFrontotemporal dementia : a clinical-pathological study
Acta neurol. belg., 2001, 101, 224-229 Clinical Pathological Conference Frontotemporal dementia : a clinical-pathological study A. MICHOTTE 1,2, S. GOLDMAN 3, P. TUGENDHAFT 4 and D. ZEGERS DE BEYL 4 1
More informationNervous System. 1. What N.S. division controls skeletal muscles? 3. What kind of neuroglia myelinates axons in the PNS?
. What N.S. division controls skeletal muscles? Nervous System SRS Review %. Central nervous system %. Peripheral nervous system %. Afferent division %. Somatic division %. Autonomic division %. Sympathetic
More informationLewy body disease (LBD) is the second most common
REGULAR ARTICLES Lewy Body Disease: Can We Diagnose It? Michelle Papka, Ph.D. Ana Rubio, M.D., Ph.D. Randolph B. Schiffer, M.D. Christopher Cox, Ph.D. The authors assessed the accuracy of published clinical
More informationUNIT 5 REVIEW GUIDE - NERVOUS SYSTEM 1) State the 3 functions of the nervous system. 1) 2) 3)
UNIT 5 REVIEW GUIDE - NERVOUS SYSTEM State the 3 functions of the nervous system. Briefly describe the general function(s) of each of the following neuron types: a) SENSORY NEURONS: b) INTERNEURONS: c)
More informationHomework Week 2. PreLab 2 HW #2 Synapses (Page 1 in the HW Section)
Homework Week 2 Due in Lab PreLab 2 HW #2 Synapses (Page 1 in the HW Section) Reminders No class next Monday Quiz 1 is @ 5:30pm on Tuesday, 1/22/13 Study guide posted under Study Aids section of website
More informationFrontotemporal dementia and dementia with Lewy bodies in a case-control study of Alzheimer s disease
International Psychogeriatrics: page 1 of 8 C 2009 International Psychogeriatric Association doi:10.1017/s1041610209009454 Frontotemporal dementia and dementia with Lewy bodies in a case-control study
More informationORIGINAL CONTRIBUTION. Clinical and Psychometric Distinction of Frontotemporal and Alzheimer Dementias
ORIGINAL CONTRIBUTION Clinical and Psychometric Distinction of Frontotemporal and Alzheimer Dementias Rajka M. Liscic, MD, PhD; Martha Storandt, PhD; Nigel J. Cairns, PhD; John C. Morris, MD Background:
More informationBrain Bank of the Brazilian Aging Brain Study Group a Collection Focused in Human Control Cases
Brain Bank of the Brazilian Aging Brain Study Group a Collection Focused in Human Control Cases Lea Tenenholz Grinberg, M.D, Ph.D Associate Professor of Pathology University of the City of São Paulo Medical
More informationAlzheimer's Disease. Dementia
Alzheimer's Disease Victor W. Henderson, MD, MS Departments of Health Research & Policy (Epidemiology) and of Neurology & Neurological Sciences Stanford University Director, Stanford Alzheimer s Disease
More informationImpaired action knowledge in amyotrophic lateral sclerosis
Impaired action knowledge in amyotrophic lateral sclerosis M. Grossman, MD C. Anderson, BA A. Khan, BA B. Avants, PhD L. Elman, MD L. McCluskey, MD Address correspondence and reprint requests to Dr. Murray
More informationSawada J, Orimoto R, Misu T, Katayama T, Aizawa H, Asanome A, Takahashi K, Saito T, Anei R, Kamada K, Miyokawa N, Takahashi T, Fujihara K, Hasebe N.
Mult Scler (2014.9) 20(10):1413-1416. A case of pathology-proven neuromyelitis optica spectrum disorder with Sjögren syndrome manifesting aphasia and apraxia due to a localized cerebral white matter lesion.
More informationbrain MRI for neuropsychiatrists: what do you need to know
brain MRI for neuropsychiatrists: what do you need to know Christoforos Stoupis, MD, PhD Department of Radiology, Spital Maennedorf, Zurich & Inselspital, University of Bern, Switzerland c.stoupis@spitalmaennedorf.ch
More informationAltered proteins in the aging brain
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1182 Altered proteins in the aging brain ADILA ELOBEID ACTA UNIVERSITATIS UPSALIENSIS UPPSALA 2016 ISSN 1651-6206 ISBN
More informationRates of cerebral atrophy differ in different degenerative pathologies
doi:10.1093/brain/awm021 Brain (2007), 130,1148^1158 Rates of cerebral atrophy differ in different degenerative pathologies Jennifer L. Whitwell, 1 Clifford R. Jack Jr, 1 Joseph E. Parisi, 2 David S. Knopman,
More informationProf Tim Anderson. Neurologist University of Otago Christchurch
Prof Tim Anderson Neurologist University of Otago Christchurch Tim Anderson Christchurch Insidious cognitive loss From subjective memory complaints (SMC) to dementia Case 1. AR. 64 yrs Male GP referral
More informationBrain Advance Access published February 25, doi: /brain/awu024 Brain 2014: Page 1 of 17 1
Brain Advance Access published February 25, 2014 doi:10.1093/brain/awu024 Brain 2014: Page 1 of 17 1 BRAIN A JOURNAL OF NEUROLOGY Asymmetry and heterogeneity of Alzheimer s and frontotemporal pathology
More informationWEBINAR SERIES: AGING IN INDIVIDUALS WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITIES
WEBINAR SERIES: AGING IN INDIVIDUALS WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITIES 1 CMS Medicare-Medicaid Coordination Office (MMCO) Established by Section 2602 of the Affordable Care Act Purpose:
More informationCognitive Ability (Decline) & Social Isolation
Cognitive Ability (Decline) & Social Isolation May 5, 2018 Women s Health Council of RI Doreen C. Putnam, CDP, CIPG DCPutnam Consulting www.dcputnamconsulting.com *** DISCLAIMER *** The information provided
More informationAtypical Progressive Supranuclear Palsy With Corticospinal Tract Degeneration
J Neuropathol Exp Neurol Copyright Ó 2006 by the American Association of Neuropathologists, Inc. Vol. 65, No. 4 April 2006 pp. 396Y405 ORIGINAL ARTICLE Atypical Progressive Supranuclear Palsy With Corticospinal
More informationORIGINAL CONTRIBUTION. Detecting Dementia With the Mini-Mental State Examination in Highly Educated Individuals
ORIGINAL CONTRIBUTION Detecting Dementia With the Mini-Mental State Examination in Highly Educated Individuals Sid E. O Bryant, PhD; Joy D. Humphreys, MA; Glenn E. Smith, PhD; Robert J. Ivnik, PhD; Neill
More informationSynaptic changes in dementia: links to cognition and behaviour
Synaptic changes in dementia: links to cognition and behaviour Paul T Francis, PhD Professor of Neurochemistry Director, Brains for Dementia Research Agenda Discuss synaptic changes in various dementias
More informationVisual Rating Scale Reference Material. Lorna Harper Dementia Research Centre University College London
Visual Rating Scale Reference Material Lorna Harper Dementia Research Centre University College London Background The reference materials included in this document were compiled and used in relation to
More informationFrontotemporal Dementia and Related Disorders: Deciphering the Enigma
NEUROLOGICAL PROGRESS Frontotemporal Dementia and Related Disorders: Deciphering the Enigma Keith A. Josephs, MST, MD In the past century, particularly the last decade, there has been enormous progress
More informationDementia. Amber Eker, MD. Assistant Professor Near East University Department of Neurology
Dementia Amber Eker, MD Assistant Professor Near East University Department of Neurology Dementia An acquired syndrome consisting of a decline in memory and other cognitive functions Impairment in social
More informationEvaluating the Patterns of Aging-Related Tau Astrogliopathy Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases
J Neuropathol Exp Neurol Vol. 76, No. 4, April 2017, pp. 270 288 doi: 10.1093/jnen/nlx007 ORIGINAL ARTICLE Evaluating the Patterns of Aging-Related Tau Astrogliopathy Unravels Novel Insights Into Brain
More informationOverview of neurological changes in Alzheimer s disease. Eric Karran
Overview of neurological changes in Alzheimer s disease Eric Karran Alzheimer s disease Alois Alzheimer 1864-1915 Auguste D. 1850-1906 Case presented November 26 th 1906 Guildford Talk.ppt 20 th March,
More information